New Advances in Cervical Cancer: From Bench to Bedside

Cervical cancer is the most common gynecologic malignancy and the fourth most common cancer in women worldwide. Over the last two decades, minimally invasive surgery (MIS) has emerged as the mainstay in the surgical management of early-stage cervical cancer, bringing advantages such as a lower opera...

Full description

Saved in:
Bibliographic Details
Published in:International journal of environmental research and public health 2022-06, Vol.19 (12), p.7094
Main Authors: D’Oria, Ottavia, Corrado, Giacomo, Laganà, Antonio Simone, Chiantera, Vito, Vizza, Enrico, Giannini, Andrea
Format: Article
Language:English
Subjects:
Cancer therapies
Cervical cancer
Cervix
Chemotherapy
Gynecological cancer
Human papillomavirus
Immunotherapy
Kinases
Malignancy
Morbidity
Poly(ADP-ribose) polymerase
Radiation therapy
Ribose
Surgery
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cervical cancer is the most common gynecologic malignancy and the fourth most common cancer in women worldwide. Over the last two decades, minimally invasive surgery (MIS) has emerged as the mainstay in the surgical management of early-stage cervical cancer, bringing advantages such as a lower operative morbidity and shorter hospital stay compared to open surgery, while maintaining comparable oncologic outcomes in numerous retrospective studies. Considering oncological patients, it is mandatory to assess the oncological outcomes and safety of this type of surgery. Moreover, there are different future outlooks on cervical cancer therapy, based on immunotherapy, target therapy, and poly-ADP-ribose polymerases (PARP) inhibitors in combination with each other, and in combination with standard chemotherapy and radiotherapy. The goal is to find an approach that is as personalized as possible.
ISSN:1660-4601
1661-7827
1660-4601
DOI:10.3390/ijerph19127094